Literature DB >> 6695822

Effects of flecainide on ventricular function: clinical and experimental correlations.

M A Josephson, N Ikeda, B N Singh.   

Abstract

Flecainide has unusual electrophysiologic properties and a high potency for the suppression of ventricular tachyarrhythmias. Little is known about its inotropic and hemodynamic actions. In isolated rabbit papillary muscle, it produced a concentration-dependent depression of contractile force, the threshold concentration being 1.0 micrograms/ml. In patients undergoing coronary angiography for ischemic heart disease and given 1 (n = 11) and 2 mg/kg (n = 11) of flecainide acetate i.v., there was no change in heart rate or mean arterial pressure. The vehicle in which i.v. flecainide was suspended had no significant effects in 6 patients in whom it was tested. Both doses produced comparable hemodynamic effects irrespective of the level of the left ventricular ejection fraction. The mean right atrial pressure increased by 12% (p less than 0.05) after 1 mg/kg and by 15% (p less than 0.01) after 2 mg/kg of the drug. The corresponding increases in mean wedge pressure were 44% (p less than 0.05) and 33% (p less than 0.05), in mean pulmonary artery pressure 27% (p less than 0.01) and 28% (p less than 0.05), in systemic vascular resistance 10% (p less than 0.05) and 9% (not significant [NS]) and in pulmonary vascular resistance 6% (NS) and 49% (p less than 0.05). Significant decreases in cardiac index (8 and 12%, p less than 0.05), stroke volume index (11 and 15%, p less than 0.01) and stroke work index (12%, p less than 0.05, and 21%, p less than 0.01) as well as in left ventricular ejection fraction (15 and 16%, p less than 0.01) were also induced by the 2 doses of flecainide.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6695822     DOI: 10.1016/0002-9149(84)90510-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  11 in total

1.  The Safety and Effectiveness of Flecainide in Children in the Current Era.

Authors:  Taylor Cunningham; Orhan Uzun; Rachel Morris; Sonia Franciosi; Amos Wong; Ida Jeremiasen; Elizabeth Sherwin; Shubhayan Sanatani
Journal:  Pediatr Cardiol       Date:  2017-08-24       Impact factor: 1.655

Review 2.  Safety of flecainide.

Authors:  Juan Tamargo; Alessandro Capucci; Philippe Mabo
Journal:  Drug Saf       Date:  2012-04-01       Impact factor: 5.606

3.  Comparative haemodynamic effects of intravenous lignocaine, disopyramide and flecainide in uncomplicated acute myocardial infarction.

Authors:  B Silke; M A Frais; S P Verma; G W Reynolds; M Hafizullah; P A Kalra; N C Jackson; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

4.  Effects of flecainide on isolated vascular smooth muscles of rat.

Authors:  F Pérez-Vizcaino; J Duarte; J Tamargo
Journal:  Br J Pharmacol       Date:  1991-11       Impact factor: 8.739

5.  Benefit-risk ratio in the treatment of tachyarrhythmias. A clinical judgement.

Authors:  F Bender
Journal:  Drugs       Date:  1985       Impact factor: 9.546

6.  The antiarrhythmic effect of flecainide on halothane-epinephrine induced arrhythmias in dogs.

Authors:  N Iwatsuki; M Takahashi; S Satoh; T Tajima
Journal:  J Anesth       Date:  1990-10       Impact factor: 2.078

Review 7.  New antiarrhythmic drugs.

Authors:  P F Nestico; J Morganroth; L N Horowitz
Journal:  Drugs       Date:  1988-03       Impact factor: 9.546

8.  Long term inotropic effects of flecainide and propafenone.

Authors:  E Henze; J Roth; W Haerer; W E Adam; M Stauch
Journal:  Eur J Nucl Med       Date:  1988

9.  Flecainide is effective against premature supraventricular and ventricular contractions during general anesthesia.

Authors:  T Saishu; N Iwatsuki; T Tajima; Y Hashimoto
Journal:  J Anesth       Date:  1994-09       Impact factor: 2.078

Review 10.  Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy.

Authors:  B Holmes; R C Heel
Journal:  Drugs       Date:  1985-01       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.